Several customers build their own testers instead of buying them.
Is it a good business? · 6 · What does its record show?
Growth lifts profit, and falls cut it
Sales, $B
3.7
3.2
2.7
2.8
3.2
5.0
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Downturn-27.7%sales, 2021 to 2023
Profit$1.20B → $501.1Moperating profit, same years
Per $158-60%kept per $1 after making it, throughout
Engineering, selling and office costs barely move, so a bigger year keeps more of each sale, and a smaller one far less.
Is it a good business? · 7 · How much room is there to grow?
Test's slice of chip spending doubled
4% → 8%test's slice of chip equipment spending
7% to 9%where its chief says it settles
6% or 7%where it may slip in 2027
Nothing is binding: orders may be cancelled, and no order book is published.
Is it a good business? · 8 · Who is in charge?
Sales beat the middle of the forecast every quarter
Since 2023Gregory Smith in charge
Late 2025Michelle Turner finance chief
Under 1%owned by insiders
Under Smith, sales beat the middle of the company's own forecast every quarter for two years.
The story right now · 9 · Why does AI need more chip testing?
AI chips are bigger and harder to test
4% → 8%test's slice of equipment spending
$1,034.4M → $2,232.6Mtest sales, first half of 2025 to 2026
Gregory Smithits chief, says the slice stops rising here
An AI processor packs many chips and memory into one package, and each must be tested longer. That doubled testing's share of chip equipment spending.
The story right now · 10 · Why did sales double, and will it continue?
Testing's slice grew; Teradyne's share did not
Chipmakers spend moreOn equipment.
Testing's slice doubles4% to 8%.
Teradyne's share holdsNear 37%.
Both ratios stop movingGrowth slows.
TSMC's spending rose a third in 2025, but its capacity barely moved: the money bought newer technology, not more chips to test.
The story right now · 11 · What changed lately?
Sales of $1.31B, just under June
$1.31Bquarterly sales
31.6 centsoperating profit per sales dollar
8.1%test's slice of equipment spending
$1.30Bnext quarter's forecast midpoint
Mixed quarter
A second big cloud customer has passed testing, but is expected to buy in the second half of 2027, not before.
The story right now · 12 · What is everyone arguing about?
Is this a growth phase or a plateau?
Many investors think
A multi-year AI growth phase, not a peak
We think
Two ratios behind the doubling have stopped moving
Against us: a second large cloud customer has passed testing, and could ramp early.
The price and our view · 13 · What is a share worth?
The price sits about a fifth above our value
$226what we think a share is worth · the last close is of that
$226our value
Attractive below $181
Neutral
Unattractive above $272
$108gloomy: growth halves and profit per $1 falls
$226our estimate: this peak is a plateau
$318sunny: growth runs a quarter faster
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · How could we be wrong?
The cycle turns, and a few buyers
The cycle turnsBiggest
Profit more than halved last time.
A handful of buyersWatch
19%, 12% and 10% of sales.
Trade rulesShowing now
Rivals are not bound by them.
Test's real sliceUnknown
Measured only by its chief.
Several customers make their own testers; Teradyne bought Infineon's in-house test team in 2025.
The price and our view · 15 · How will we know?
January's forecast decides whether growth returns
A first-quarter forecast above $1.33BGood sign
The second cloud customer ramping earlyGood sign
A fourth quarter under $1.25BBad sign
JAN 202727
Fourth-quarter 2026 results and new targets, 27 January. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: we turn positive if the shares fall a fifth below our estimate, and negative if they rise a fifth above it.
The price and our view · 16 · So, what do we think?
AI doubled its sales, but its share did not grow
$226our value
Attractive below $181
Neutral
Unattractive above $272
NeutralMedium conviction
Teradyne makes the machines that test finished chips, and sales doubled on the AI build-out. But its market share did not grow, the trend that doubled the market stops here, and the price sits above our value. Neutral.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
Every chip is tested before it ships, twice: once on the silicon wafer and again after it is packaged. Teradyne's testers are racks of instruments that drive signals into the chip at full speed and decide pass or fail.
The buyers are chipmakers, the foundries that make chips for others, and the firms that package and test them. Its annual report names Advantest, SPEA and Cohu as rivals.
How it makes money
Teradyne is paid when a customer buys a tester, and again for servicing it. So its sales follow how much chipmakers spend on new equipment, and that swings with the chip cycle. From 2021 to 2023 sales fell 27.7% and operating profit fell by more than half.
Growth and profit
What growth costs
Growth makes Teradyne more profitable. The cost of each machine rises with sales, but engineering, selling and office costs barely move, so a bigger year keeps more of each sale. The same costs bite when sales fall, as the last downturn showed.
Its record
The numbers
Is it growing?Fast
Sales grew 75% over the twelve months to Sep 2026, faster than the 13% in the year to Dec 2025.
Is it profitable?Strong
Operating margin is 32%, up from 19% in the year to Dec 2023.
Does growth pay off?Pays off
Running costs take 27¢ of each sales dollar, about where it was (27¢) in the year to Dec 2021.
Does it earn good returns?Strong
Each dollar put into the business earns 42% a year after tax, about where it was (40%) in the year to Dec 2021.
Is it making cash?Strong
It turned 20% of sales into free cash, $1.02B over the last twelve months.
Is the balance sheet safe?Net cash
It holds $461M of cash against $0 of debt, $461M more cash than it owes.
Are shares being diluted?Shrinking
The share count fell 14% in 4.7 years, and pay in shares costs 1.6% of sales.
Why it wins
The evidence
A customer writes its test programme for one platform's software, then proves chip by chip that it gives the same answer as the reference machine. Moving to a rival means doing all of that again, which Teradyne's chief executive says takes nine to twelve months.
Amkor, one of the largest packaging-and-test firms, confirms it from outside: its annual report says it concentrates spending on standard tester platforms to keep them busy. The flip side is that share barely moves either way. Teradyne's sits near 37%.
Who could beat it
The rivals in full
Advantest, the market leader, is the rival that matters: its sales rose 44.7% in the year to March 2026, at an operating margin of 44.2%. Cohu, which already sells the equipment around Teradyne's machines, now calls itself a growing tester maker. And several customers build their own.
Each rival
Advantest Corporation6857.T
The tester itself in system-on-chip production test: the buyer qualifies the device on a V93000 line and buys Advantest capacity instead of UltraFLEXplus capacity for the same sockets.
The tester in lower-complexity device segments. Cohu's own annual report describes it as 'a growing provider of semiconductor test equipment' on top of the handlers and interface hardware it already sells around Teradyne's machines, so it is moving up into the box rather than beside it.
FANUC, ABB and Yaskawa6954.TABBN.SW6506.T
The robot arm on the factory line: traditional industrial-robot makers selling into the same electronics and assembly cells Teradyne's collaborative robots target.
Mobile robots and the automation around them in material handling, where Teradyne's 10-K names it among the competitors of its autonomous mobile robots.
Keysight TechnologiesKEYS
Board, wireless and defence test instruments, which a buyer can buy from a larger instrument maker instead of Teradyne's Product Test line.
How big it could get
The market and who has signed
The market
The market is the testers chipmakers buy each year, a slice of everything they spend on equipment. That slice rose from near 4% in 2023 to 8% in the first five months of 2026.
The chief executive says it settles at 7% to 9% and may slip to 6% or 7% in 2027.
Who has signed
Nothing is binding. Teradyne shipped a first order to a maker of graphics chips for AI in the June quarter, value undisclosed, and memory makers ordered more than twice what they were billed. Both are orders a customer may cancel, and no backlog figure is published.
Who runs it
Leaders, pay and the cash
Who runs it
Gregory Smith has run Teradyne since 2023, after leading its chip-testing and robot businesses; Michelle Turner became finance chief in late 2025. Under Smith, sales have beaten the middle of the company's own forecast every quarter for two years. Insiders own well under 1% of the company. Their bonus rides mostly on sales growth, profit margin and internal goals the company does not publish; their long-term shares on profit and on how the stock does against the market.
The last report
The latest report
Teradyne sold $1.31B and guided the next quarter to $1.30B at the midpoint
What it did to the thesis Mixed quarter
The guide landed between our two lines, so the view holds. June is still the biggest quarter of 2026 on the company's own midpoint, and margins are guided lower. Growth next year is promised, but dated to late 2027.
The report
The September quarter brought $1.31B of sales, a little below June's $1.33B, and 31.6 cents of every sales dollar was operating profit. The company's own guide for the fourth quarter is $1.25B to $1.35B, so its midpoint of $1.30B is again under June.
The call added two things. Chip testing was 8.1% of chipmakers' equipment spending in the first eight months of 2026, inside the 7% to 9% range its chief executive has said it settles in. And the second big cloud customer has passed testing and is expected to buy capacity in the second half of 2027, not before.
What's happening now
The background
The test has been read: on 27 October Teradyne reported the September quarter and guided the fourth to a $1.30B midpoint, under June's $1.33B. The next one is the January results, with the updated long-term target model.
The spending underneath is real. TSMC, the largest foundry, spent US$40.9B on equipment and buildings in 2025, a third more than in 2024, and guides US$52B to US$56B for 2026. But its wafer capacity barely moved, at about 17 million a year: the money bought newer technology, not more chips to test.
Where we disagree
Both sides in full
The market
This is a multi-year AI growth phase, not a cycle peak, and analysts keep raising their ratings and targets.
We believe
The doubling came from two ratios that have stopped moving: test's slice of equipment spending, and Teradyne's own share, which never moved.
The argument
Consensus puts 2027 sales 21% above 2026. What it may be missing sits in the July call, not the results release: a chief executive capping his own market, and a weighting that turns the guidance into a plateau nobody wrote down.
The evidence against us: positive ratings rose from 60.0% to 70.6% since May, though the panel shrank from 20 analysts to 17. And a second large cloud customer has passed correlation; a production ramp there would move share for the first time.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
What the price assumes
Sales growth in the first year, then slowing as ours does, at the same profit per sale.
The price assumed
26.8%
Our estimate
23%
Measured at the close of
6 Nov 2026
The three cases
Bear case$108
Growth runs at half the analysts' path, 12% and 12%, the margin settles a fifth lower at 19.0%, and new capital earns only the 8% rate: the downturn test.
Our value$226
Revenue grows 23% and 23% over three years, the analysts' path (C63), then fades toward 4%, closing 30% of the gap each year; the margin settles at its five-year average of 23.8%, not today's cycle peak.
Bull case$318
Growth runs a quarter above the analysts' path, 29% and 29%, the margin reaches 26.2%, and new capital earns 15%.
The bet
Seen as a bet
The bet is on Robotics alone: robot arms that work beside people and factory robots that move goods. It lost money for three years and shrank last year, and only now nears breaking even.
Chip and product testing, held at last year's profit, valued at an ordinary equipment maker's price, cover under half of today's price. Even if robots grow as management promises, the whole company would be worth about half of today: an expensive bet.
If robots never earn, shareholders keep the testing businesses and the cash.
What could go wrong
Every risk
The risks
The cycle turns
From 2021 to 2023 sales fell 27.7% and operating profit fell from $1.20B to $501.1M.
A handful of buyers
One customer was 19% of 2025 sales, and two others 12% and 10%.
Trade rules
Export restrictions already limit it where some rivals are not bound by them, its annual report says.
Customers build their own
Several make their own testers; Teradyne bought Infineon's in-house test team in 2025.
What we still do not know
Test's real slice of chipmakers' equipment spending, measured by anyone other than Teradyne's chief executive.
Who the 19% customer is, and whether it overlaps the two customers at 12% and 10%.
Whether the second large cloud customer, now past testing with capacity buys expected in the second half of 2027, ramps earlier.
What changes our view
Every route to a new view
Every route to a new view
→ Attractive
The share price falls to about $181, 80% of what we think the business is worth.
→ Unattractive
The share price rises to about $272, 20% above what we think the business is worth.
Research reopens
Test's slice of chip-equipment spending rises above 9%, past the chief executive's own ceiling, and stays there through 2027. Teradyne's stated share of testing for complex processor chips rises above 40% in its 2027 results.
The next test
It supports the case if
First-quarter 2027 revenue guided above $1,329.0 million; or a named production ramp at the second hyperscaler pulled into the first half of 2027; or a stated test share of chip-equipment spending above 9%.
It pressures the case if
Fourth-quarter revenue below $1.25 billion; or the first quarter guided below the fourth-quarter result; or the updated model assuming operating margin below 30%; or the stated test share falling back below 7%.
We would also be wrong if
The two smaller businesses, product testing and robots, grow to a quarter of pre-tax profit, making this more than one business.
The verdict
Scores and how we weighed it
The scores
Growth
3 of 4
Business quality
3 of 4
Financial position
4 of 4
Execution record
3 of 4
Per share capture
3 of 4
Potential
2 of 4
Risk profile
2 of 4
Valuation
3 of 4
Evidence quality
3 of 4
How we weighed it
ValueMixed
The price is about at our value, with the bear case far below.
BusinessPositive
Machines that test finished chips, a solid business.
GrowthMixed
The market grew while its share did not; growth next year is promised but dated late.
RisksNegative
The cycle turns, a few buyers dominate, trade rules bind it and customers build their own testers.
RivalsMixed
There is no filed cohort to compare, so the price is judged on its own.
The groupMixed
Chip-equipment names move together on news about chipmakers' spending.
Latest newsMixed
The guide landed between our lines and margins are guided lower.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.